Global CD244 (2B4) Antibody Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CD244 (2B4) Antibody Market Research Report 2024
CD244 (2B4) Antibody is an antibody directed against the CD244 protein in the human immune system.
According to Mr Accuracy reports’s new survey, global CD244 (2B4) Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD244 (2B4) Antibody market research.
CD244 is a cell surface molecule that belongs to the immunoglobulin superfamily and is mainly expressed on natural killer cells, T cells and certain subsets of B cells. By binding to the CD244 molecule, this antibody can regulate the activation, proliferation and function of immune cells, thereby affecting the regulation and effect of the immune response. Since CD244 plays an important role in regulating immune cell interactions, the potential application of CD244 antibodies in immunotherapy research and the treatment of tumors, autoimmune diseases and other diseases has attracted much attention.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD244 (2B4) Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sino Biological, Inc.
LifeSpan BioSciences, Inc
Thermo Fisher
BioLegend
Abbexa
Abcam
Cell Signaling Technology, Inc.
Arigo Biolaboratories Corp.
Boster Biological Technology
GeneTex
MyBiosource, Inc.
CUSABIO
Creative Diagnostics
Bio-Techne
AMSBIO
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
ELISA
Western Blot
Immunofluorescence
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD244 (2B4) Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global CD244 (2B4) Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD244 (2B4) Antibody market research.
CD244 is a cell surface molecule that belongs to the immunoglobulin superfamily and is mainly expressed on natural killer cells, T cells and certain subsets of B cells. By binding to the CD244 molecule, this antibody can regulate the activation, proliferation and function of immune cells, thereby affecting the regulation and effect of the immune response. Since CD244 plays an important role in regulating immune cell interactions, the potential application of CD244 antibodies in immunotherapy research and the treatment of tumors, autoimmune diseases and other diseases has attracted much attention.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD244 (2B4) Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sino Biological, Inc.
LifeSpan BioSciences, Inc
Thermo Fisher
BioLegend
Abbexa
Abcam
Cell Signaling Technology, Inc.
Arigo Biolaboratories Corp.
Boster Biological Technology
GeneTex
MyBiosource, Inc.
CUSABIO
Creative Diagnostics
Bio-Techne
AMSBIO
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
ELISA
Western Blot
Immunofluorescence
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD244 (2B4) Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices